Antibody-drug conjugates (ADCs) are a relatively new and important class of biopharmaceuticals, integral to targeted therapy. By conjugating agents to antibodies, scientists and clinicians are hoping to selectively target only diseased cells and tissue, thereby minimizing collateral damage to healthy tissue. ADCs are particularly promising in combating diseases such as cancer, where existing treatments possess considerable side effects due to an inability to fully delineate between healthy and diseased cells.
In this webinar from Wolfe Laboratories, learn about:
- What antibody-drug conjugates are and how they function
- How to analyze and characterize ADCs
- Developing ADC processes
- Developing ADC formulations
